Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus

Abstract

Daptomycin is highly active against Staphylococcus aureus, including multidrug-resistant strains and those with reduced susceptibility to vancomycin. However, daptomycin-non-susceptible (DapNS) strains [minimum inhibitory concentration (MIC) >1mg/L] have been derived clinically and in vitro. The mechanism(s) by which this occurs is incompletely understood, but existing data indicate that it is multifactorial. DapNS derivatives of one laboratory and three clinical strains of S. aureus produced using gradient plates were evaluated. The DapNS phenotype included increases in glycopeptide and nisin MICs and in some instances defective autolysis and reduced susceptibility to lysostaphin lysis. Amino acid substitutions in MprF, YycG (WalK), or both, were identified in all DapNS strains. Reduced cytochrome c binding and ability of daptomycin to depolarise whole cells correlated with the DapNS phenotype, consistent with an increase in cell surface positivity. Gene expression data revealed increased expression of vraS, one member of a two-component system involved in the regulation of cell wall biosynthesis, in three of five DapNS strains. The pathway to the DapNS phenotype is not linear, as variable genetic and phenotypic changes may result in identical increases in MICs.